Rafael Holdings reported a full fiscal year 2026 net loss of $29.6 million, a slight improvement from the prior year. The company's cash and cash equivalents stood at $22.1 million, while R&D expenses significantly increased due to subsidiary Cyclo Therapeutics.
Rafael Holdings (RFL) reported a net loss of $29.6 million for fiscal year 2026, a marginal improvement from the previous year. While the Q4 loss narrowed due to reduced G&A expenses, a significant increase in R&D spending, primarily at its subsidiary Cyclo Therapeutics (CYTH), led to higher overall R&D costs. The company's cash position of $22.1 million as of July 31, 2026, is a key concern given the ongoing losses and increased R&D burn. This filing indicates continued operational losses and a potentially limited cash runway, which could necessitate future financing. For traders, the short-term implication is likely negative for RFL due to the persistent losses and cash burn, while CYTH's increased R&D could be seen as a long-term opportunity if it leads to successful drug development, but also a short-term drain on RFL's resources.